Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Glaukos Corporation

Capitalization 5.63B 4.92B 4.45B 4.25B 7.74B 521B 8.04B 53.13B 21.06B 249B 21.13B 20.69B 899B P/E ratio 2026 *
-119x
P/E ratio 2027 * 358x
Enterprise value 5.45B 4.77B 4.31B 4.12B 7.49B 504B 7.79B 51.44B 20.38B 241B 20.46B 20.03B 870B EV / Sales 2026 *
8.89x
EV / Sales 2027 * 6.85x
Free-Float
96.76%
Yield 2026 *
-
Yield 2027 * -
1 day-0.79%
1 week-9.94%
Current month-19.42%
1 month-11.37%
3 months-10.89%
6 months+17.23%
Current year-14.07%
1 week 95.87
Extreme 95.87
106.78
1 month 95.87
Extreme 95.87
123.16
Current year 93.96
Extreme 93.96
130.23
1 year 73.16
Extreme 73.16
130.23
3 years 45.38
Extreme 45.38
163.71
5 years 33.33
Extreme 33.33
163.71
10 years 15
Extreme 15
163.71
Manager TitleAgeSince
Chief Executive Officer 65 31/12/2000
Director of Finance/CFO 56 31/03/2022
President 50 31/03/2022
Director TitleAgeSince
Chairman 65 30/12/2021
Director/Board Member 71 30/06/2014
Director/Board Member 58 30/06/2014
Change 5d. change 1-year change 3-years change Capi.($)
-0.79%-9.94%-5.06%+104.68% 5.63B
-0.13%-7.62%-8.87%+22.16% 129B
+0.60%-2.84%+14.08%+4.22% 14.04B
+0.31%+1.02%-28.95%-63.39% 6.21B
+1.01%-0.90%+36.58%+15.21% 2.65B
+0.52%-1.17%-12.87%-22.99% 2.03B
-2.82%-0.12%+15.01%-17.28% 1.88B
+0.64%-6.94%-63.85%-75.44% 1.68B
+0.63%-9.65%+261.82%+252.99% 1.32B
Average -0.00%-2.92%+23.10%+24.46% 18.26B
Weighted average by Cap. -0.06%-6.54%-4.96%+19.95%

Financials

2026 *2027 *
Net sales 613M 536M 484M 463M 843M 56.72B 876M 5.78B 2.29B 27.1B 2.3B 2.25B 97.87B 782M 684M 618M 591M 1.08B 72.37B 1.12B 7.38B 2.93B 34.57B 2.94B 2.87B 125B
Net income -50.33M -43.99M -39.75M -38.02M -69.15M -4.66B -71.89M -475M -188M -2.22B -189M -185M -8.03B 14.65M 12.81M 11.57M 11.07M 20.13M 1.36B 20.92M 138M 54.77M 647M 54.97M 53.81M 2.34B
Net Debt -180M -157M -142M -136M -247M -16.63B -257M -1.7B -672M -7.94B -675M -660M -28.69B -276M -241M -218M -208M -379M -25.51B -394M -2.6B -1.03B -12.19B -1.04B -1.01B -44.03B
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Employees
1,094
Date Price Change Volume
13/03/26 97.02 $ -0.79% 646,412
12/03/26 97.79 $ -4.93% 866,909
11/03/26 102.86 $ -0.28% 508,164
10/03/26 103.15 $ -2.49% 875,043
09/03/26 105.78 $ -1.81% 952,958
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
97.02USD
Average target price
134.79USD
Spread / Average Target
+38.93%

Quarterly revenue - Rate of surprise

SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW